The development of brain metastases in patients with different therapeutic strategies for metastatic renal cell cancer

Sophie H. A. E. Derks,Edgar L. van der Meer,Arjen Joosse,Maja J. A. de Jonge,Cleo Slagter,Joost W. Schouten,Esther Oomen‐de Hoop,Marion Smits,Martin J. van den Bent,Joost L. M. Jongen,Astrid A. M. van der Veldt

DOI: https://doi.org/10.1002/ijc.34984

2024-05-05

International Journal of Cancer

Abstract:What's New? Brain metastasis (BM) affects a significant proportion of patients with metastatic renal cell carcinoma (mRCC). Little is known, however, about ways in which different mRCC treatment strategies impact BM development. Here, the authors investigated the timing of BM during different treatment strategies in a real‐world cohort of mRCC patients at the Erasmus MC Cancer Institute in the Netherlands. Active surveillance (AS) was a common initial strategy for mRCC. However, systemic treatment was more effective in potentially delaying metastasis to the brain. The findings imply a need for careful AS evaluation and a possible benefit to early initiation of systemic mRCC treatment. A diagnosis of brain metastasis (BM) significantly affects quality of life in patients with metastatic renal cell cancer (mRCC). Although systemic treatments have shown efficacy in mRCC, active surveillance (AS) is still commonly used in clinical practice. In this single‐center cohort study, we assessed the impact of different initial treatment strategies for metastatic RCC (mRCC) on the development of BM. All consecutive patients diagnosed with mRCC between 2011 and 2022 were included at the Erasmus MC Cancer Institute, the Netherlands, and a subgroup of patients with BM was selected. In total, 381 patients with mRCC (ECM, BM, or both) were identified. Forty‐six patients had BM of whom 39 had metachronous BM (diagnosed ≥1 month after ECM). Twenty‐five (64.1%) of these 39 patients with metachronous BM had received prior systemic treatment for ECM and 14 (35.9%) patients were treatment naive at BM diagnosis. The median BM‐free survival since ECM diagnosis was significantly longer (p = .02) in previously treated patients (29.0 [IQR 12.6–57.0] months) compared to treatment naive patients (6.8 [IQR 1.0–7.0] months). In conclusion, patients with mRCC who received systemic treatment for ECM prior to BM diagnosis had a longer BM‐free survival as compared to treatment naïve patients. These results emphasize the need for careful evaluation of treatment strategies, and especially AS, for patients with mRCC.

oncology